Source Paper
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V <sub>1b</sub> receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, Jean Wagnon, Marc Pascal et al.
Proceedings of the National Academy of Sciences • 2002
Social Defeat Paradigm
Objective: An atypical anxiety model measuring stress-induced anxiety following social defeat exposure to assess anxiolytic-like effects of test compounds
Gather these items before starting the experiment. Check off items as you prepare.
Equipment1
Not specified • Not specified • Not specified • Not mentioned
1 item available from ConductScience
Estimated: $1,890.00
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Social Defeat Exposure
Subjects are exposed to social defeat as a stressor to induce anxiety-like behavior
Note: This is an atypical anxiety model involving traumatic stress exposure
View evidence from paper
“social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.)”
Test Compound Administration
SSR149415 administered at specified doses via oral (p.o.) or intraperitoneal (i.p.) routes
Note: Doses ranged from 1-30 mg/kg depending on test model
View evidence from paper
“SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.)”
Anxiety Assessment
Behavioral measures of anxiety-like responses are recorded following social defeat exposure and compound administration
Note: Specific behavioral measures not detailed in provided text
View evidence from paper
“social defeat-induced anxiety rodent models of anxiety”